Background: This study aimed to assess the effect of a fixed combination of Red Ginseng and Red Sage (RG-RS) on the gene expression of neuronal cells to evaluate the potential impacts on cellular functions and predict its relevance in the treatment of stress and aging-related diseases and disorders.
Methods: Gene expression profiling was conducted by transcriptome-wide mRNA microarray analyses of murine HT22 hippocampal cell culture after treatment with RG-RS preparation. Ingenuity pathway analysis (IPA) was performed with datasets of significantly upregulated or downregulated genes and the expected effects on the physiological and cellular function and the diseases were identified.
Results: RG-RS deregulates 1028 genes associated with cancer and 139 with metastasis, suggesting a predicted decrease in tumorigenesis, the proliferation of tumor cells, tumor growth, metastasis, and an increase in apoptosis and autophagy by their effects on the various signaling and metabolic pathways, including the inhibition of Warburg's aerobic glycolysis, estrogen-mediated S-phase entry signaling, osteoarthritis signaling, and the super-pathway of cholesterol biosynthesis.
Conclusion: The results of this study provide evidence of the potential efficacy of the fixed combination of Red Ginseng ( C.A. Mey.) and Red Sage/Danshen ( Bunge) in cancer. Further clinical and experimental studies are required to assess the efficacy and safety of RG-RS in preventing the progression of cancer, osteoarthritis, and other aging-related diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696821 | PMC |
| http://dx.doi.org/10.3390/ph15111345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety study on switching from intravenous to fixed‑dose subcutaneous formulation of pertuzumab and trastuzumab.
Mol Clin Oncol
March 2025
Department of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
To the best of our knowledge, there have been no reports from clinical settings regarding safety information on a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PHESGO) when switched from the intravenous formulation of pertuzumab and trastuzumab in Japan. The lack of information on switching from the intravenous formulation to PHESGO in clinical settings may contribute to hesitation in making the switch. The present study analyzed the safety of 51 patients with breast or colorectal cancer treated with PHESGO.
View Article and Find Full Text PDFTriazination/IEDDA Cascade Modular Strategy Installing Pyridines/Pyrimidines onto Tyrosine Enables Peptide Screening and Optimization.
J Am Chem Soc
January 2025
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P. R. China.
Modular chemical postmodification of peptides is a promising strategy that supports the optimization and innovation of hit peptide therapeutics by enabling rapid derivatization. However, current methods are primarily limited to traditional bio-orthogonal strategies and chemical ligation techniques, which require the preintroduction of non-natural amino acids and impose fixed methods that limit peptide diversity. Here, we developed the Tyrosine-1,2,3-Triazine Ligation (YTL) strategy, which constructs novel linkages (pyridine and pyrimidine) through a "one-pot, two-step" process combining SAr and IEDDA reactions, promoting modular post modification of Tyr-containing peptides.
View Article and Find Full Text PDFFirst-line glaucoma monotherapy medication patterns in Finland during 1995-2019 based on a population-based study.
PLoS One
January 2025
Faculty of Medicine and Health Technology, Department of Ophthalmology, Tampere University, Tampere, Finland.
Background: The long-term patterns in first-line glaucoma medication are not well established. Exploring these in longitudinal and population-based settings would provide information for the healthcare systems to plan glaucoma care accordingly.
Objective: To evaluate patterns in first-line glaucoma monotherapy in Finland during 1995-2019 based on nationwide survey and register data.
Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFFixed start method for repetitive project scheduling with simulated annealing.
Heliyon
January 2025
Engineering School of Sustainable Infrastructure and Environment, University of Florida, Gainesville, FL, United States.
This research deals with the high project completion variability by presenting a new method to decrease such variability in repetitive construction projects. To achieve this, a Fixed Start Method (FSM) -where the starts of each activity with a high level of probabilistic confidence for the planned project duration are fixed- was applied, where the high level of probabilistic confidence obtained was optimized with the use of the metaheuristic algorithm called Simulated Annealing (SA). This procedure evaluated the project completion in a case study based on the coefficient of variance (COV) of the resulting standard deviation, mean, and temperature selected for the SA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!